Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1990 3
1991 1
1993 1
1994 1
1995 2
1998 3
1999 1
2001 1
2003 1
2004 1
2005 2
2006 2
2007 1
2008 2
2009 5
2010 3
2011 2
2012 7
2013 5
2014 6
2015 7
2016 5
2017 6
2018 9
2019 7
2020 4
2021 6
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

92 results
Results by year
Filters applied: . Clear all
Page 1
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Munir T, et al. Among authors: mulligan sp. Am J Hematol. 2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13. Am J Hematol. 2019. PMID: 31512258 Free PMC article. Clinical Trial.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators. Byrd JC, et al. Among authors: mulligan sp. N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31. N Engl J Med. 2014. PMID: 24881631 Free PMC article. Clinical Trial.
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.
Wierda WG, Rawstron A, Cymbalista F, Badoux X, Rossi D, Brown JR, Egle A, Abello V, Cervera Ceballos E, Herishanu Y, Mulligan SP, Niemann CU, Diong CP, Soysal T, Suzuki R, Tran HTT, Wu SJ, Owen C, Stilgenbauer S, Ghia P, Hillmen P. Wierda WG, et al. Among authors: mulligan sp. Leukemia. 2021 Nov;35(11):3059-3072. doi: 10.1038/s41375-021-01241-1. Epub 2021 Jun 24. Leukemia. 2021. PMID: 34168283 Free PMC article. Review.
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR. Byrd JC, et al. Among authors: mulligan sp. Blood. 2019 May 9;133(19):2031-2042. doi: 10.1182/blood-2018-08-870238. Epub 2019 Mar 6. Blood. 2019. PMID: 30842083 Free PMC article. Clinical Trial.
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. Stilgenbauer S, et al. Among authors: mulligan sp. J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1. J Clin Oncol. 2018. PMID: 29715056 Clinical Trial.
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. Stilgenbauer S, et al. Among authors: mulligan sp. Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10. Lancet Oncol. 2016. PMID: 27178240 Clinical Trial.
Molecular pathogenesis of chronic lymphocytic leukaemia.
Crassini K, Stevenson WS, Mulligan SP, Best OG. Crassini K, et al. Among authors: mulligan sp. Br J Haematol. 2019 Sep;186(5):668-684. doi: 10.1111/bjh.16102. Epub 2019 Jul 31. Br J Haematol. 2019. PMID: 31364161 Review.
Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia.
Fatima N, Crassini KR, Thurgood L, Shen Y, Christopherson RI, Kuss B, Mulligan SP, Best OG. Fatima N, et al. Among authors: mulligan sp. Cancer Drug Resist. 2020 May 11;3(3):532-549. doi: 10.20517/cdr.2019.111. eCollection 2020. Cancer Drug Resist. 2020. PMID: 35582439 Free PMC article. Review.
Chronic lymphocytic leukemia, skin and other second cancers.
Mulligan SP, Shumack S, Guminski A. Mulligan SP, et al. Leuk Lymphoma. 2019 Dec;60(13):3104-3106. doi: 10.1080/10428194.2019.1665669. Epub 2019 Sep 24. Leuk Lymphoma. 2019. PMID: 31547730 No abstract available.
92 results